Reports

Sale

Hepatic Encephalopathy Treatment Market

Hepatic Encephalopathy Treatment Market Size, Share, Report: By Drug Class: Antibiotics, Laxatives, L-ornithine, L-aspartate, Others; By Diagnosis: Blood Tests, CT Scan, Liver Functioning Tests (LFT), Others; By Treatment; By Route of Administration; By End User, By Distribution Channels; Regional Analysis; Supplier Landscape; 2024-2032

Hepatic Encephalopathy Treatment Market Outlook

The hepatic encephalopathy treatment market size was valued at USD 1.6 billion in 2023, driven by the rising incidence of liver cirrhosis across the 7 major markets. The market is expected to grow at a CAGR of 5.7% during the forecast period of 2024-2032, with the values likely to rise from USD 1.7 billion in 2024 to USD 2.6 billion by 2032.

 

Hepatic Encephalopathy Treatment: Introduction

Hepatic encephalopathy is a temporary neurological disorder that occurs due to a severe liver disease. The damaged liver fails to clear out the toxins effectively and toxins build up reaches the brain through the blood stream. It causes cognitive impairment and affects brain function. Hepatic encephalopathy is commonly managed by antibiotics and laxatives. However, the treatment may vary depending upon the symptoms and overall health of the patient.

 

Hepatic Encephalopathy Treatment Market Analysis

The hepatic encephalopathy treatment market demand is mostly driven by the increasing prevalence of liver-associated diseases which include liver cirrhosis, hepatitis, and fatty liver.

 

Nonabsorbable disaccharides, such as lactulose or lactitol, are considered as the first in-line treatment for the condition. They function by lowering the absorption of ammonia in the body. Another commonly used treatment method is the use of antibiotics. They are used to alter the gut microbiota to create a more favourable microbiome that leads to decreased endogenous bacterial production of ammonia. Rifaximin, Neomycin and Metronizadole are frequently prescribed to treat the condition.

 

Dietary treatment alternatives that naturally lower down the ammonia levels in the body can also be applied. Using intravenous L-ornithine-L-aspartate has been proven helpful in lowering the severity of the condition in some patients. If the condition persists due to complete liver damage, then liver transplant is the last alternative recommended by healthcare professionals.

 

Apart from pharmaceuticals, the hepatic encephalopathy treatment market value is also driven by the rising advancements in diagnostics. Tests like electroencephalography are used to determine the severity of the condition and facilitate effective treatment based on it.

 

Hepatic Encephalopathy Treatment Market Segmentation

Market Breakup by Drug Class

  • Antibiotics
  • Laxatives
  • L-ornithine
  • L-aspartate
  • Others

 

Market Breakup by Diagnosis

  • Blood Tests
  • CT Scan
  • Liver Functioning Tests (LFT)
  • Others

 

Market Breakup by Treatment

  • Medication
  • Surgery
  • Others

 

Market Breakup by Route of Administration

  • Oral
  • Injectable
  • Intravenous
  • Rectal
  • Others

 

Market Breakup by End User

  • Hospitals
  • Homecare
  • Speciality Clinics
  • Others

 

Market Breakup by Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

 

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan

 

Hepatic Encephalopathy Treatment Market Overview

The United States has been proactive in mitigating the rising burden of liver diseases. The region has held a substantial percentage of the hepatic encephalopathy treatment market share. With increasing drug development and other treatment alternatives, there has been significant emphasis on educating the population on identifying the early stages of liver damage. This has been made possible through awareness campaigns and initiatives set up by government as well as private institutions. In July 2023, the World Health Organization launched “One Life, One Liver” campaign, aimed at protecting liver health.

 

Alcohol consumption, obesity and sedentary lifestyle are major factors contributing to liver diseases. Hence, Europe is also a significant player of the hepatic encephalopathy treatment market. With well-equipped medical infrastructure and staff, it can pioneer the treatment market by bringing groundbreaking innovations to improve the efficacy of medicines.

 

With a high percentage of geriatric population, the Asia Pacific region is expected to witness rapid hepatic encephalopathy treatment market growth in the coming years. The region has been experiencing major mergers and acquisitions among impactful companies, which are anticipated to fuel market growth. With an influx of foreign investments, the medical infrastructure is also improving.

 

Hepatic Encephalopathy Treatment Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Salix Pharmaceuticals
  • Mallinckrodt plc.
  • Merck & Co., Inc.
  • Bausch Health
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson Services, Inc.
  • Eisai Co., Ltd
  • AbbVie Inc.
  • Hikma Pharmaceuticals PLC
  • Vedanta Biosciences
  • Patricia Bloom
  • Umecrine Cognition
  • Axcella Health Inc.
  • Pfizer Inc.
  • Rebiotix

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Diagnosis
  • Treatment
  • Route of Administration
  • End User 
  • Distribution Channels 
  • Reguonal
Breakup by Drug Class
  • Antibiotics    
  • Laxatives
  • L-ornithine  
  • L-aspartate  
  • Others 
Breakup by Diagnosis
  • Blood Tests    
  • CT Scan    
  • Liver Functioning Tests (LFT)    
  • Others 
Breakup by Treatment
  • Medication  
  • Surgery
  • Others 
Breakup by Route of Administration
  • Oral
  • Injectable  
  • Intravenous  
  • Rectal  
  • Others  
Breakup by End User 
  • Hospitals 
  • Homecare
  • Speciality Clinics 
  • Others 
Breakup by Distribution Channels 
  • Hospital Pharmacy  
  • Retail Pharmacy  
  • Online Pharmacy 
  • Others 
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Salix Pharmaceuticals
  • Mallinckrodt plc.
  • Merck & Co., Inc. 
  • Bausch Health
  • Takeda Pharmaceutical Company Limited 
  • Johnson & Johnson Services, Inc.
  • Eisai Co., Ltd
  • AbbVie Inc.
  • Hikma Pharmaceuticals PLC
  • Vedanta Biosciences
  • Patricia Bloom
  • Umecrine Cognition
  • Axcella Health Inc.
  • Pfizer Inc.
  • Rebiotix

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Hepatic Encephalopathy Treatment Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Hepatic Encephalopathy Epidemiology Analysis – 7MM
    5.1    7MM Epidemiology Scenario Overview (2017-2032)
    5.2    United States Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
    5.3    EU-4 and United Kingdom Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
        5.3.1    Germany Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
        5.3.2    France Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
        5.3.3    Italy Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
        5.3.4    Spain Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
        5.3.5    United Kingdom Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
    5.4    Japan Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
6    Hepatic Encephalopathy Treatment Market Overview – 7MM
    6.1    Hepatic Encephalopathy Treatment Market Historical Value (2017-2023) 
    6.2    Hepatic Encephalopathy Treatment Market Forecast Value (2024-2032)
7    Hepatic Encephalopathy Treatment Market Landscape – 7MM
    7.1    Amyotrophic Lateral Sclerosis: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Hepatic Encephalopathy Treatment Product Landscape
        7.2.1    Analysis by Drug Class
        7.2.2    Analysis by Treatment
        7.2.3    Analysis by Route of Administration
8    Hepatic Encephalopathy Treatment Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Hepatic Encephalopathy Treatment Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Hepatic Encephalopathy Treatment Market Segmentation – 7MM
    11.1    Hepatic Encephalopathy Treatment Market by Drug Class
        11.1.1    Market Overview 
        11.1.2    Antibiotics    
        11.1.3    Laxatives
        11.1.4    L-ornithine  
        11.1.5    L-aspartate  
        11.1.6    Others 
    11.2    Hepatic Encephalopathy Treatment Market by Diagnosis
        11.2.1    Market Overview 
        11.2.2    Blood Tests    
        11.2.3    CT Scan    
        11.2.4    Liver Functioning Tests (LFT)    
        11.2.5    Others 
    11.3    Hepatic Encephalopathy Treatment Market by Treatment 
        11.3.1    Market Overview 
        11.3.2    Medication   
        11.3.3    Surgery  
        11.3.4    Others 
    11.4    Hepatic Encephalopathy Treatment Market by Route of Administration
        11.4.1    Market Overview
        11.4.2    Oral
        11.4.3    Injectable  
        11.4.4    Intravenous  
        11.4.5    Rectal  
        11.4.6    Others  
    11.5    Hepatic Encephalopathy Treatment Market by End User 
        11.5.1    Market Overview 
        11.5.2    Hospitals 
        11.5.3    Homecare
        11.5.4    Speciality Clinics 
        11.5.5    Others 
    11.6    Hepatic Encephalopathy Treatment Market by Distribution Channels 
        11.6.1    Market Overview 
        11.6.2    Hospital Pharmacy  
        11.6.3    Retail Pharmacy  
        11.6.4    Online Pharmacy 
        11.6.5    Others 
    11.7    Hepatic Encephalopathy Treatment Market by Region
        11.7.1    Market Overview
        11.7.2    United States
        11.7.3    EU-4 and the United Kingdom
            11.7.3.1    Germany
            11.7.3.2    France
            11.7.3.3    Italy
            11.7.3.4    Spain
            11.7.3.5    United Kingdom    
        11.7.4    Japan
12    United States Hepatic Encephalopathy Treatment Market
    12.1    Hepatic Encephalopathy Treatment Market Historical Value (2017-2023) 
    12.2    Hepatic Encephalopathy Treatment Market Forecast Value (2024-2032)
    12.3    Hepatic Encephalopathy Treatment Market by Drug Class
    12.4    Hepatic Encephalopathy Treatment Market by Treatment 
13    EU-4 and United Kingdom Hepatic Encephalopathy Treatment Market
    13.1    Hepatic Encephalopathy Treatment Market Historical Value (2017-2023) 
    13.2    Hepatic Encephalopathy Treatment Market Forecast Value (2024-2032)
    13.3    Germany Hepatic Encephalopathy Treatment Market Overview
        13.3.1    Hepatic Encephalopathy Treatment Market by Drug Class
        13.3.2    Hepatic Encephalopathy Treatment Market by Treatment 
    13.4    France Hepatic Encephalopathy Treatment Market Overview
        13.4.1    Hepatic Encephalopathy Treatment Market by Drug Class 
        13.4.2    Hepatic Encephalopathy Treatment Market by Treatment 
    13.5    Italy Hepatic Encephalopathy Treatment Market Overview
        13.5.1    Hepatic Encephalopathy Treatment Market by Drug Class
        13.5.2    Hepatic Encephalopathy Treatment Market by Treatment 
    13.6    Spain Hepatic Encephalopathy Treatment Market Overview
        13.6.1    Hepatic Encephalopathy Treatment Market by Drug Class
        13.6.2    Hepatic Encephalopathy Treatment Market by Treatment 
    13.7    United Kingdom Hepatic Encephalopathy Treatment Market Overview
        13.7.1    Hepatic Encephalopathy Treatment Market by Drug Class
        13.7.2    Hepatic Encephalopathy Treatment Market by Treatment 
14    Japan Hepatic Encephalopathy Treatment Market
    14.1    Hepatic Encephalopathy Treatment Market Historical Value (2017-2023) 
    14.2    Hepatic Encephalopathy Treatment Market Forecast Value (2024-2032)
    14.3    Hepatic Encephalopathy Treatment Market by Drug Class
    14.4    Hepatic Encephalopathy Treatment Market by Treatment 
15    Regulatory Framework
    15.1    Regulatory Overview
        15.1.1    US FDA
        15.1.2    EU EMA
        15.1.3    JAPAN PMDA
16    Patent Analysis
    16.1    Analysis by Type of Patent
    16.2    Analysis by Publication year
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Patent Age
    16.5    Analysis by CPC Analysis
    16.6    Analysis by Patent Valuation 
    16.7    Analysis by Key Players
17    Grants Analysis
    17.1    Analysis by year
    17.2    Analysis by Amount Awarded
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Grant Application
    17.5    Analysis by Funding Institute
    17.6    Analysis by NIH Departments
    17.7    Analysis by Recipient Organization 
18    Clinical Trials Analysis
    18.1     Analysis by Trial Registration Year
    18.2    Analysis by Trial Status
    18.3    Analysis by Trial Phase
    18.4    Analysis by Therapeutic Area
    18.5    Analysis by Geography
19    Funding and Investment Analysis
    19.1    Analysis by Funding Instances
    19.2    Analysis by Type of Funding
    19.3    Analysis by Funding Amount
    19.4    Analysis by Leading Players
    19.5    Analysis by Leading Investors
    19.6    Analysis by Geography
20    Partnerships and Collaborations Analysis
    20.1    Analysis by Partnership Instances
    20.2    Analysis by Type of Partnership
    20.3    Analysis by Leading Players
    20.4    Analysis by Geography
21    Supplier Landscape
    21.1    Salix Pharmaceuticals   
        21.1.1    Financial Analysis 
        21.1.2    Product Portfolio 
        21.1.3    Demographic Reach and Achievements 
        21.1.4    Mergers and Acquisitions 
        21.1.5    Certifications 
    21.2    Mallinckrodt plc. 
        21.2.1    Financial Analysis 
        21.2.2    Product Portfolio 
        21.2.3    Demographic Reach and Achievements 
        21.2.4    Mergers and Acquisitions 
        21.2.5    Certifications 
    21.3    Merck & Co., Inc. 
        21.3.1    Financial Analysis 
        21.3.2    Product Portfolio 
        21.3.3    Demographic Reach and Achievements 
        21.3.4    Mergers and Acquisitions 
        21.3.5    Certifications 
    21.4    Bausch Health 
        21.4.1    Financial Analysis 
        21.4.2    Product Portfolio 
        21.4.3    Demographic Reach and Achievements 
        21.4.4    Mergers and Acquisitions 
        21.4.5    Certifications 
    21.5    Takeda Pharmaceutical Company Limited 
        21.5.1    Financial Analysis 
        21.5.2    Product Portfolio 
        21.5.3    Demographic Reach and Achievements 
        21.5.4    Mergers and Acquisitions 
        21.5.5    Certifications 
    21.6    Johnson & Johnson Services, Inc. 
        21.6.1    Financial Analysis 
        21.6.2    Product Portfolio 
        21.6.3    Demographic Reach and Achievements 
        21.6.4    Mergers and Acquisitions 
        21.6.5    Certifications 
    21.7    Eisai Co., Ltd
        21.7.1    Financial Analysis 
        21.7.2    Product Portfolio 
        21.7.3    Demographic Reach and Achievements 
        21.7.4    Mergers and Acquisitions 
        21.7.5    Certifications 
    21.8      AbbVie Inc. 
        21.8.1    Financial Analysis 
        21.8.2    Product Portfolio 
        21.8.3    Demographic Reach and Achievements 
        21.8.4    Mergers and Acquisitions 
        21.8.5    Certifications 
    21.9    Hikma Pharmaceuticals PLC 
        21.9.1    Financial Analysis 
        21.9.2    Product Portfolio 
        21.9.3    Demographic Reach and Achievements 
        21.9.4    Mergers and Acquisitions 
        21.9.5    Certifications 
    21.10    Vedanta Biosciences  
        21.10.1    Financial Analysis 
        21.10.2    Product Portfolio 
        21.10.3    Demographic Reach and Achievements 
        21.10.4    Mergers and Acquisitions 
        21.10.5    Certifications 
    21.11     Patricia Bloom
        21.11.1    Financial Analysis 
        21.11.2    Product Portfolio 
        21.11.3    Demographic Reach and Achievements 
        21.11.4    Mergers and Acquisitions 
        21.11.5    Certifications 
    21.12     Umecrine Cognition
        21.12.1    Financial Analysis 
        21.12.2    Product Portfolio 
        21.12.3    Demographic Reach and Achievements 
        21.12.4    Mergers and Acquisitions 
        21.12.5    Certifications 
    21.13    Axcella Health Inc.
        21.13.1    Financial Analysis 
        21.13.2    Product Portfolio 
        21.13.3    Demographic Reach and Achievements 
        21.13.4    Mergers and Acquisitions 
        21.13.5    Certifictions 
    21.14    Pfizer Inc.
        21.14.1    Financial Analysis 
        21.14.2    Product Portfolio 
        21.14.3    Demographic Reach and Achievements 
        21.14.4    Mergers and Acquisitions 
        21.14.5    Certifications 
    21.15    Rebiotix 
        21.15.1    Financial Analysis 
        21.15.2    Product Portfolio 
        21.15.3    Demographic Reach and Achievements 
        21.15.4    Mergers and Acquisitions 
        21.15.5    Certifications 
22    Hepatic Encephalopathy Treatment Market- Distribution Model (Additional Insight)
    22.1    Overview 
    22.2    Potential Distributors 
    22.3    Key Parameters for Distribution Partner Assessment 
23    Key Opinion Leaders (KOL) Insights (Additional Insight)
24    Company Competitiveness Analysis (Additional Insight)

    24.1    Very Small Companies
    24.2    Small Companies
    24.3    Mid-Sized Companies
    24.4    Large Companies
    24.5    Very Large Companies
25    Payment Methods (Additional Insight)
    25.1    Government Funded
    25.2    Private Insurance
    25.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 1.6 billion in 2023, driven by rising incidence of liver cirrhosis.

The market is anticipated to grow at a CAGR of 5.7% during the forecast period of 2024-2032, likely to reach a market value of USD 2.6 billion by 2032.

The market demand is driven by increasing burden of liver diseases and increasing alcohol consumption around the 7 major markets.

The key trends which are bolstering the market growth include the increasing focus on combination therapies and increasing drug approvals for treating hepatic encephalopathy.

The drug classes in the market include antibiotics, laxatives, L-ornithine, and L-aspartate, among others.

The treatments in the market are blood tests, CT scan, and liver functioning tests (LFT), among others.

The different routes of administration are oral, injectable, intravenous, and rectal, among others.

The end-users in the market are hospitals, homecare, and specialty clinics, among others.

The distribution channels available in the market are hospital pharmacy, retail pharmacy, and online pharmacy, among others.

The major regions of the market include the United States, Japan, EU-4 and the United Kingdom. EU-4 comprises of Germany, France, Italy, and Spain.

Key players involved in the market are Salix Pharmaceuticals, Mallinckrodt plc., Merck & Co., Inc., Bausch Health, Takeda Pharmaceutical Company Limited, Johnson & Johnson Services, Inc., Eisai Co., Ltd, AbbVie Inc., Hikma Pharmaceuticals PLC, Vedanta Biosciences, Patricia Bloom, Umecrine Cognition, Axcella Health Inc., Pfizer Inc., and Rebiotix.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER